Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hitler's madcap mega-railway would have linked Berlin with India - 2German Easter peace marches draw tens of thousands
- 3Skeleton of famed musketeer possibly found in Dutch church
- 4General Atlantic says ‘biggest mistake’ would be pulling back on Gulf deals
- 5Barry Manilow reveals lung cancer diagnosis and plans to undergo surgery: 'It's pure luck' it was 'found so early'
- Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- A Concise History Of The Entertainment world
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- What is a Trump Gold Card? U.S. launches $1 million immigration visas
- Tourist trade in Greece and Cyprus suffering from Iran war effects
- Flu season is just beginning, but doctors are already on high alert
- 6 Objections for an Ocean side Wedding
